Written procedures have not been developed for the reporting to FDA of post marketing adverse drug experiences.
See every finding in this document View official sourceBy Category
Regulatory reporting and change control Findings
in this category 525 findings drawn from 517 published documents. The most recent cases are below; the full set is in search.
See all Regulatory reporting and change control findingsWhich agency cited it
Companies with the most findings
Recent findings
An annual report was not submitted within 60 days of the anniversary date of U.S.
See every finding in this document View official sourceAn MDR report was not submitted within 30 days ofreceiving or otherwise becoming aware of information that reasonably suggests that a marketed device has malfunctioned and would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.
View official sourceThe change control system was inadequate for ensuring changes are properly documented, evaluated, and/or approved.
See every finding in this document View official sourceThe change control system was inadequate for ensuring changes are properly documented, evaluated, and/or approved.
See every finding in this document View official sourceThe change control system was inadequate for ensuring changes are properly documented, evaluated, and/or approved.
See every finding in this document View official sourceNarrow by agency
Other categories
These findings are a record of the moment each document was published. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out — do not read them as the current state; check the regulator's official announcements for the latest status. Counts are measured from public data as of 2026-09-04, and findings are extracted automatically from the regulator's published documents. “View official source” on each case links directly to that document.
